Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.
Arcidiacono, Maria V.
MetadataShow full item record
Background: Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in atheromatosis progression in CKD patients. Methods: Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results: The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions: Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.
Is part ofPlos One, 2018, vol. 13, num. 9, p. e0203716
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by (c) Arcidiacono, Maria V. et al., 2018
Showing items related by title, author, creator and subject.
Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease Anguiano, Lidia; Riera, Marta; Pascual, Julio; Valdivielso Revilla, José Manuel; Barrios, Clara; Betriu i Bars, M. Àngels; Mojal, Sergi; Fernández i Giráldez, Elvira; Soler, María José (Oxford University Press, 2015)
Fernández-Laso, V.; Méndez-Barbero, N.; Valdivielso Revilla, José Manuel; Betriu i Bars, M. Àngels; Fernández i Giráldez, Elvira; Egido, Jesús; Martín-Ventura, JL.; Blanco-Colio, LM. (Elsevier, 2017-03-31)BACKGROUND AND AIMS: Circulating soluble TNF-like weak inducer of apoptosis (sTWEAK) concentrations are related to the presence of chronic kidney disease (CKD) and cardiovascular disease (CVD). However, there are no data ...
High levels of hemoglobin promote carotid adventitial vasa vasorum neoangiogenesis in chronic kidney disease Arcidiacono, Maria V.; Martínez Alonso, Montserrat; Belart, Montserrat; Vilar, Ana; Martín, Marisa; Craver Hospital, Lourdes; Betriu i Bars, M. Àngels; Mauricio Puente, Dídac; Valdivielso Revilla, José Manuel; Fernández i Giráldez, Elvira; Borràs, Mercè (Hindawi, 2017-01-04)Chronic kidney disease (CKD) patients, characterized by traditional and nontraditional risk factors, are prone to develop atheromatosis and thus cardiovascular events and mortality. The angiogenesis of the adventitial vasa ...